SCHEMBL1109801

SCHEMBL1109801

CNCCCOc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1B P28222 2/20 1.00
HTR1D P28221 1/20 0.88
L3MBTL1 Q9Y468 2/20 0.68
DRD4 P21917 6/20 0.67
DRD2 P14416 5/20 0.67
DRD3 P35462 5/20 0.67
KCNA3 P22001 1/20 0.62
KDM4E B2RXH2 3/20 0.61
ALDH1A1 P00352 2/20 0.59
MEN1 O00255 1/20 0.59
HTT P42858 1/20 0.59
KMT2A Q03164 1/20 0.59
CACNA1B Q00975 1/20 0.57
MTNR1A P48039 1/20 0.56
MTNR1B P49286 1/20 0.56
RECQL P46063 1/20 0.56
HRH1 P35367 1/20 0.56
NSD2 O96028 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
CHRNB2 P17787 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6849557 0.94 HTR1B (0.88) HTR1BHTR1DL3MBTL1DRD4DRD2
SCHEMBL595753 0.93 HTR1B (1.00) HTR1BHTR1DL3MBTL1DRD4DRD2
SCHEMBL13886634 0.92 HTR1B (0.85) HTR1BHTR1DL3MBTL1DRD4DRD2
SCHEMBL6850933 0.92 HTR1B (0.85) HTR1BHTR1DL3MBTL1DRD4DRD2
Hydrochloric Acid SCHEMBL10921722 0.91 HTR1B (0.96) HTR1BHTR1DL3MBTL1DRD4DRD2
Iodide SCHEMBL30481083 0.91 HTR1B (0.96) HTR1BHTR1DL3MBTL1DRD4DRD2
Tetradecane SCHEMBL29054434 0.85 HTR1B (0.76) HTR1BHTR1DL3MBTL1DRD4DRD2
SCHEMBL10801216 0.85 HTR1B (0.73) HTR1BHTR1DL3MBTL1KDM4EALDH1A1
SCHEMBL19327366 0.84 HTR1B (0.71) HTR1BHTR1DL3MBTL1KDM4EALDH1A1
SCHEMBL19327367 0.84 HTR1B (0.71) HTR1BHTR1DL3MBTL1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250345785-A1 ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS BIO RAD LABORATORIES INC (US) 2025-11-13 US claimed
US-11896969-B2 Anionic exchange-hydrophobic mixed mode chromatography resins BIO-RAD LABORATORIES, INC. (US) 2024-02-13 US claimed
US-9000107-B2 Process for producing polydienes BRIDGESTONE CORPORATION (JP) 2015-04-07 US claimed
US-6489349-B1 TREATING AN AUTOIMMUNE DISORDER WITH AN ALKYLAMINE SUBSTITUTED PYRIDINE TARGACEPT, INC. 2002-12-03 US claimed
EP-1171127-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATIVES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION Targacept, Inc. (US) 2002-01-16 EP claimed
US-6255288-B1 THERAPY FOR BONE DISORDERS NOVARTIS CORPORATION 2001-07-03 US claimed
US-6166048-A Pharmaceutical compositions for inhibition of cytokine production and secretion TARGACEPT, INC. (US) 2000-12-26 US claimed
WO-2000062767-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION TARGACEPT, INC. (US) 2000-10-26 WO claimed
EP-0998934-A1 REMEDIES FOR INTRAMEDULLARY DISEASES TORAY INDUSTRIES, INC. (JP) 2000-05-10 EP claimed
EP-0600834-A1 Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing CIBA-GEIGY AG (CH) 1994-06-08 EP claimed
EP-0550385-A1 Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers CIBA-GEIGY AG (CH) 1993-07-07 EP claimed
US-20250345785-A1 ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS BIO RAD LABORATORIES INC (US) 2025-11-13 US disclosed
US-12364978-B2 Anionic exchange-hydrophobic mixed mode chromatography resins BIO-RAD LABORATORIES, INC. (US) 2025-07-22 US disclosed
US-20240261775-A1 ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS BIO-RAD LABORATORIES, INC. 2024-08-08 US disclosed
US-11896969-B2 Anionic exchange-hydrophobic mixed mode chromatography resins BIO-RAD LABORATORIES, INC. (US) 2024-02-13 US disclosed
US-5133972-A TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS CIBA-GEIGY CORPORATION (US) 1992-07-28 US disclosed
US-5036058-A Regulates calcium metabolism CIBA-GEIGY CORPORATION (US) 1991-07-30 US disclosed
EP-0407344-A2 Pharmaceutical preparation for topical application CIBA-GEIGY AG (CH) 1991-01-09 EP disclosed
EP-0387194-A1 N-substituted aminoalkane-diphosphonic acids CIBA-GEIGY AG (CH) 1990-09-12 EP disclosed
EP-0318036-A2 Phenoxypropyl derivatives FUJIREBIO KABUSHIKI KAISHA (JP) 1989-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250345785-A1 ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS ABCG2, SLC7A1, MSR1 HTR1B 1932/4885HTR1D 2519/4885L3MBTL1 3154/4885
US-12364978-B2 Anionic exchange-hydrophobic mixed mode chromatography resins ABCG2, SLC7A1, MSR1 HTR1B 1932/4885HTR1D 2519/4885L3MBTL1 3154/4885
US-20240261775-A1 ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS ABCG2, SLC7A1, MSR1 HTR1B 1932/4885HTR1D 2519/4885L3MBTL1 3154/4885
US-11896969-B2 Anionic exchange-hydrophobic mixed mode chromatography resins ABCG2, SLC7A1, MSR1 HTR1B 1932/4885HTR1D 2519/4885L3MBTL1 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.